Drug Discoveries & Therapeutics
Online ISSN : 1881-784X
Print ISSN : 1881-7831
ISSN-L : 1881-7831
Letter
Less is more: A novel single-tablet regimen with two-drugs, dolutegravir/lamivudine
Jianjun SunHongzhou Lu
著者情報
ジャーナル フリー

2021 年 15 巻 4 号 p. 225-226

詳細
抄録

Combined antiretroviral therapy (cART) has significantly reduced human immunodeficiency virus (HIV) associated morbidity and mortality and turned HIV infection into a manageable chronic condition. However, lifelong cART is still required. Two-drug regimens could reduce the number of HIV agents and lower the adverse events caused by lifelong medication. A new two-drug regimen, DEVATO, consisting of dolutegravir and lamivudine has durable efficacy, is well-tolerated, and has a high barrier to viral resistance, which is why it is recommended as a new first-line treatment option for people living with HIV infection.

著者関連情報
© 2021 International Research and Cooperation Association for Bio & Socio-Sciences Advancement
前の記事
feedback
Top